Fig. 3From: Recombinant growth hormone therapy in children with Turner Syndrome in Korea: a phase III Randomized TrialHeight standard deviation scores at baseline, 13, 26, 39, and 52 weeks and change in height standard deviation score for annualized height velocity from baseline at 52-week. a Height standard deviation scores at baseline, 13, 26, 39, and 52 weeks; b Change in height standard deviation score of annualized height velocity from baseline at 52-weekBack to article page